CN115667258A - 氟代吡咯并吡啶类化合物及其应用 - Google Patents

氟代吡咯并吡啶类化合物及其应用 Download PDF

Info

Publication number
CN115667258A
CN115667258A CN202180037895.4A CN202180037895A CN115667258A CN 115667258 A CN115667258 A CN 115667258A CN 202180037895 A CN202180037895 A CN 202180037895A CN 115667258 A CN115667258 A CN 115667258A
Authority
CN
China
Prior art keywords
compound
added
reaction
ethyl acetate
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037895.4A
Other languages
English (en)
Inventor
方堃
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Lingfang Biomedical Technology Co ltd
Original Assignee
Shenzhen Lingfang Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Lingfang Biomedical Technology Co ltd filed Critical Shenzhen Lingfang Biomedical Technology Co ltd
Publication of CN115667258A publication Critical patent/CN115667258A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

本发明公开了一类氟代吡咯并吡啶类化合物。具体公开了式(Ⅱ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202180037895.4A 2020-05-29 2021-05-26 氟代吡咯并吡啶类化合物及其应用 Pending CN115667258A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020104784329 2020-05-29
CN202010478432 2020-05-29
CN202110139687 2021-02-01
CN2021101396877 2021-02-01
PCT/CN2021/096143 WO2021238999A1 (zh) 2020-05-29 2021-05-26 氟代吡咯并吡啶类化合物及其应用

Publications (1)

Publication Number Publication Date
CN115667258A true CN115667258A (zh) 2023-01-31

Family

ID=78745589

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037895.4A Pending CN115667258A (zh) 2020-05-29 2021-05-26 氟代吡咯并吡啶类化合物及其应用

Country Status (7)

Country Link
US (1) US20230212165A1 (zh)
EP (1) EP4159734A1 (zh)
JP (1) JP7418051B2 (zh)
KR (1) KR20230012586A (zh)
CN (1) CN115667258A (zh)
AU (1) AU2021282122B2 (zh)
WO (1) WO2021238999A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112047938B (zh) * 2019-06-06 2022-11-22 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN116178366A (zh) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019036641A1 (en) * 2017-08-17 2019-02-21 Board Of Regents, The University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
WO2019050889A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS
WO2019154365A1 (zh) * 2018-02-07 2019-08-15 南京明德新药研发有限公司 一种atr抑制剂及其应用
CN116178366A (zh) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
MX2020000386A (es) 2017-07-13 2020-08-06 Univ Texas Inhibidores heterociclicos de la cinasa atr.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019036641A1 (en) * 2017-08-17 2019-02-21 Board Of Regents, The University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
WO2019050889A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS
WO2019154365A1 (zh) * 2018-02-07 2019-08-15 南京明德新药研发有限公司 一种atr抑制剂及其应用
CN116178366A (zh) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法

Also Published As

Publication number Publication date
JP7418051B2 (ja) 2024-01-19
WO2021238999A1 (zh) 2021-12-02
JP2023526490A (ja) 2023-06-21
AU2021282122A1 (en) 2023-02-09
EP4159734A1 (en) 2023-04-05
US20230212165A1 (en) 2023-07-06
AU2021282122B2 (en) 2023-09-21
KR20230012586A (ko) 2023-01-26

Similar Documents

Publication Publication Date Title
WO2021259331A1 (zh) 八元含n杂环类化合物
CN107849017A (zh) 作为magl抑制剂的1,1,1‑三氟‑3‑羟基丙‑2‑基氨基甲酸酯衍生物及1,1,1‑三氟‑4‑羟基丁‑2‑基氨基甲酸酯衍生物
WO2021110168A1 (zh) 作为erk抑制剂的螺环类化合物及其应用
CN112771045B (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
CN115667258A (zh) 氟代吡咯并吡啶类化合物及其应用
CN108884093A (zh) 6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂*多巴胺D3配体
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
WO2021204111A1 (zh) 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物
CN113825755A (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
CN114728966B (zh) 作为mnk抑制剂的吡咯并三嗪类化合物
CN114761407A (zh) 作为高选择性ros1抑制剂的化合物及其应用
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN114555600A (zh) 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
WO2023160572A1 (zh) 吡唑类衍生物、药物组合物及应用
WO2023001069A1 (zh) 大环酰胺类化合物及其应用
CN113811530B (zh) 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
CN113474345B (zh) 作为ret抑制剂的含氮螺环衍生物
WO2022143693A1 (zh) 噻吩并[2,3-c]吡咯-4-酮衍生物
WO2023241618A1 (zh) 氨基嘧啶类化合物及其应用
WO2024051727A1 (zh) 吡唑类衍生物、药物组合物及应用
CN113286594A (zh) 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
WO2021104470A1 (zh) 抗hbv的1,7-萘啶类化合物
CN114957259A (zh) 氰基取代的芳香双环类化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Room 504, Building C1, No. 201 Linghu Avenue, Xinwu District, Wuxi City, Jiangsu Province, 214111

Applicant after: Wuxi Lingfang Biopharmaceutical Technology Co.,Ltd.

Address before: 518045 1312, building 1, Changfu Jinmao building, south of Shihua Road, Fubao community, Fubao street, Futian District, Shenzhen, Guangdong Province

Applicant before: Shenzhen Lingfang Biomedical Technology Co.,Ltd.

CB02 Change of applicant information